Oseltamivir is one of the most commonly used anti-influenza A virus drugs in clinic.However

when the World Health Organization updated the list of essential medicines in 2017

oseltamivir was adjusted from the core drug to the auxiliary drug

and oseltamivir was considered to be deleted in the next issue of the list.The latest guidelines in various countries still recommended oseltamivir as the first-line drug

and which was recommended to be applied as soon as possible within 48 h after onset

some studies recommended high-dose therapy for patients in severe cases.This paper retrospectively analyzes the relevant literature on the different decisions made by WHO and national guidelines

summarizes the evidence-based medical evidence for the downgrade of oseltamivir and the recommendation of oseltamivir

and discusses the corresponding therapeutic dose for patients in severe cases.